-+ 0.00%
-+ 0.00%
-+ 0.00%

SENTI BIOSCIENCES HOLDINGS ANNOUNCES POSITIVE FDA RMAT MEETING ON REGISTRATIONAL CLINICAL AND CMC STRATEGY FOR SENTI-202 IN RELAPSED/REFRACTORY AML, ALONG WITH IMPORTANT EFFICACY AND DURABILITY UPDATES ON THE SENTI-202 CLINICAL PROGRAM

Reuters·05/14/2026 12:40:00

Please log in to view news